Your browser doesn't support javascript.
loading
Cutting Edge: Negative Regulation of Inflammasome Activation by TRAF1 Can Limit Gout.
Mirzaesmaeili, Ali; Zangiabadi, Safoura; Raspanti, Jonathan; Akram, Ali; Inman, Robert D; Abdul-Sater, Ali A.
Afiliación
  • Mirzaesmaeili A; School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
  • Zangiabadi S; School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
  • Raspanti J; School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
  • Akram A; School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
  • Inman RD; Spondylitis Program, Division of Rheumatology, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; and.
  • Abdul-Sater AA; Department of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada.
J Immunol ; 210(5): 531-535, 2023 03 01.
Article en En | MEDLINE | ID: mdl-36637223
ABSTRACT
Secretion of IL-1ß, a potent cytokine that plays a key role in gout pathogenesis, is regulated by inflammasomes. TRAF1 has been linked to heightened risk to inflammatory arthritis. In this article, we show that TRAF1 negatively regulates inflammasome activation to limit caspase-1 and IL-1ß secretion in human and mouse macrophages. TRAF1 reduces linear ubiquitination and subsequent oligomerization of the adapter protein, ASC. i.p. injection of monosodium urate crystals resulted in increased inflammatory cell infiltrates and IL-1ß production in Traf1 knockout mice compared with wild type littermates. In a model of monosodium urate crystal-induced gout, Traf1 knockout mice exhibited more swelling in the knee joints, increased infiltration of inflammatory cells, and higher expression of proinflammatory cytokines. In summary, this study identifies TRAF1 as a key regulator of IL-1ß production and a potential therapeutic target for inflammasome-driven diseases such as gout.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inflamasomas / Gota Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Immunol Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inflamasomas / Gota Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Immunol Año: 2023 Tipo del documento: Article País de afiliación: Canadá